Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus dexamethasone in elderly unfit patients with newly diagnosed multiple myeloma
KCT0003558Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Celgene Corporation. Started Mar 2019; status: completed.
02
Drugs
lenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0003558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003558.